Theralase Technologies Inc. TLTFF

Primary Symbol: V.TLT

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New BCG-Unresponsive NMIBC Treatment Review Study

<< Previous

Bullboard Posts

Next >>

Post by Eoganachton Nov 21, 2024 11:28am

241 Views

Post# 36323898

New BCG-Unresponsive NMIBC Treatment Review Study

European Urology Oncology

Available online 15 November 2024

David D’Andrea, Hugh Mostafid, Paolo Gontero, Shahrokh Shariat, Ashish Kamat, Alexandra Masson-Lecomte, Maximilian Burger, Morgan Rouprt

Unmet Need in Non–muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gurin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group

"A total of 57 studies published between 1998 and 2024, with 68 unique study arms and consisting of 2589 patients, were identified. The 3-mo overall response rate (ORR) across all studies, complete response rate (CRR) in concomitant carcinoma in situ (CIS) or CIS only disease, and recurrence-free rate (RFR) in papillary disease were estimated to be 52.4% (95% confidence interval [CI]: 45.4–59.2), 52.8% (95% CI: 42.9–62.6), and 26.4% (95% CI: 13.3–45.6), respectively. The 12-mo ORR, CRR, and RFR were estimated to be 78% (95% CI: 52.9–91.8), 27.8% (95% CI: 21.3–35.4), and 25.4% (95% CI: 18.2–34.2), respectively."

The study includes the toxicity events for all 4 BCG-Unresponsive NMIBC approved treatments. TLD1433 had better safety results (zero toxicity events) than all approved treatments.

	Grade 1-2	Grade 3	Grade 4	Grade 5

Valrubicin	19%	0%	0%	0%
Adstiladrin (NF)	8.3%	0%	0%	0%
Pembrolizumab	10.9%	2%	0%	0%
Anktiva (NAI)	39%	3.7%	1.2%	1.2%

TLD1433	0%	0%	0%	0%